Your browser is no longer supported. Please, upgrade your browser.
CWBR [NASD]
CohBar, Inc.
Index- P/E- EPS (ttm)-0.28 Insider Own6.00% Shs Outstand86.06M Perf Week-15.30%
Market Cap29.04M Forward P/E- EPS next Y-0.23 Insider Trans3.50% Shs Float67.23M Perf Month-21.16%
Income-17.40M PEG- EPS next Q-0.06 Inst Own16.30% Short Float1.49% Perf Quarter-66.61%
Sales- P/S- EPS this Y-9.40% Inst Trans49.88% Short Ratio0.52 Perf Half Y-72.27%
Book/sh0.22 P/B1.42 EPS next Y8.00% ROA-96.60% Target Price4.12 Perf Year-81.88%
Cash/sh0.16 P/C1.94 EPS next 5Y- ROE-115.40% 52W Range0.33 - 2.27 Perf YTD-10.43%
Dividend- P/FCF- EPS past 5Y-22.50% ROI- 52W High-86.19% Beta2.44
Dividend %- Quick Ratio6.80 Sales past 5Y- Gross Margin- 52W Low-5.32% ATR0.03
Employees11 Current Ratio6.80 Sales Q/Q- Oper. Margin- RSI (14)30.08 Volatility8.21% 9.40%
OptionableNo Debt/Eq0.03 EPS Q/Q16.90% Profit Margin- Rel Volume0.41 Prev Close0.34
ShortableYes LT Debt/Eq0.00 EarningsNov 15 AMC Payout- Avg Volume1.93M Price0.31
Recom2.00 SMA20-17.26% SMA50-31.21% SMA200-68.61% Volume784,761 Change-6.92%
Mar-15-21Initiated Aegis Capital Buy $6
Jan-13-22 01:38PM  
Jan-03-22 09:00AM  
Dec-31-21 11:22AM  
Dec-17-21 09:00AM  
Nov-29-21 09:00AM  
Nov-19-21 09:47AM  
Nov-15-21 04:02PM  
Nov-03-21 08:33AM  
Nov-02-21 01:14AM  
Nov-01-21 09:00AM  
Oct-28-21 02:45PM  
08:45AM  
Oct-27-21 04:01PM  
Oct-13-21 09:00AM  
Sep-15-21 09:00AM  
Sep-08-21 09:00AM  
Sep-02-21 04:05PM  
Aug-20-21 09:46AM  
Aug-16-21 09:00AM  
Aug-12-21 12:50PM  
Aug-10-21 04:04PM  
04:02PM  
Aug-04-21 04:05PM  
Jul-14-21 09:00AM  
Jun-10-21 09:00AM  
May-17-21 04:02PM  
03:15PM  
May-03-21 09:00AM  
Apr-27-21 08:30AM  
Apr-22-21 09:56AM  
Apr-21-21 09:00AM  
Apr-14-21 09:00AM  
Mar-30-21 04:02PM  
02:45PM  
Mar-29-21 09:00AM  
Mar-16-21 04:05PM  
09:00AM  
Mar-12-21 09:00AM  
Mar-02-21 09:00AM  
Feb-25-21 09:00AM  
Feb-09-21 09:00AM  
Jan-20-21 09:00AM  
Jan-11-21 09:00AM  
Dec-09-20 09:00AM  
Nov-19-20 09:00AM  
Nov-16-20 04:01PM  
03:15PM  
Nov-09-20 03:30PM  
Nov-02-20 09:00AM  
07:35AM  
Oct-29-20 09:00AM  
Oct-27-20 09:00AM  
Oct-26-20 09:00AM  
Oct-15-20 04:05PM  
Oct-08-20 09:00AM  
Oct-05-20 09:00AM  
Sep-29-20 04:05PM  
Sep-10-20 04:05PM  
Sep-04-20 11:24AM  
Sep-03-20 08:45AM  
Aug-28-20 04:05PM  
Aug-26-20 08:30AM  
Aug-25-20 04:55PM  
Aug-24-20 09:00AM  
Aug-13-20 04:03PM  
Aug-05-20 09:00AM  
Jul-30-20 09:00AM  
Jul-07-20 09:00AM  
Jul-06-20 09:00AM  
Jun-30-20 09:00AM  
Jun-17-20 09:00AM  
Jun-02-20 09:00AM  
May-27-20 09:00AM  
May-14-20 04:02PM  
May-13-20 09:00AM  
May-05-20 09:00AM  
May-01-20 11:00AM  
Apr-30-20 09:00AM  
Apr-19-20 09:21AM  
Apr-14-20 08:30AM  
Mar-30-20 08:45AM  
Mar-12-20 04:02PM  
03:00PM  
08:30AM  
Mar-02-20 04:30PM  
Jan-28-20 09:00AM  
Jan-22-20 09:00AM  
Jan-08-20 09:00AM  
Dec-23-19 08:04PM  
Dec-16-19 09:00AM  
Nov-06-19 04:04PM  
Nov-05-19 09:00AM  
Oct-24-19 09:00AM  
Oct-23-19 08:45AM  
Oct-15-19 09:00AM  
Aug-07-19 04:05PM  
Jul-31-19 04:05PM  
Jun-10-19 09:00AM  
Jun-05-19 09:00AM  
May-29-19 09:00AM  
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Petkevich MishaDirectorOct 28Buy0.58167,00096,175407,609Nov 01 09:15 AM
Sarret Joseph J.Chief Executive OfficerAug 18Buy1.1220,00022,40020,000Aug 19 09:00 AM
Cundy Kenneth CChief Scientific OfficerAug 11Option Exercise0.7310,0007,30020,000Aug 13 04:02 PM
Cundy Kenneth CChief Scientific OfficerAug 11Sale2.0110,00020,10010,000Aug 13 04:02 PM
Cundy Kenneth CChief Scientific OfficerFeb 16Option Exercise0.7310,0007,30020,000Feb 18 04:30 PM
Cundy Kenneth CChief Scientific OfficerFeb 16Sale1.9010,00019,00010,000Feb 18 04:30 PM